The Dana-Farber/Harvard Cancer Center (DF/HCC) is an innovative collaboration between seven participating institutions, including:
- Beth Israel Deaconess Medical Center (BIDMC),
- Brigham and Women’s Hospital (BWH),
- Children’s Hospital Boston (CHB),
- Dana-Farber Cancer Institute (DFCI),
- Harvard Medical School (HMS),
- Harvard School of Public Health (HSPH), and
- Massachusetts General Hospital (MGH).
The DF/HCC was formed in 1999 as a formal collaboration expanded from the original Dana-Farber Cancer Center which had been designated by the National Cancer Institute (NCI) as a Comprehensive Cancer Center, and has been supported by the NCI for the past 36 years. DF/HCC was formally funded as a 7 institution consortium and an NCI-designated Comprehensive Cancer Center in 2000. The cancer research and treatment collaborations sponsored across the participating institutions by the DF/HCC combines the disciplines of population science, clinical science, and basic research, to facilitate the development of novel and improved modalities for the prevention and treatment of cancer.
The population sciences programs and cores are linked below. Those for basic and clinical sciences can be reached via the general program and core links. Membership information can be found via the DF/HCC website link.
Population Research Programs
- Biostatistics Program
- Cancer Epidemiology Program
- Outcomes Research Program
- Palliative Care
- Cancer Risk Reduction Program
Population Science Core Facilities
- Community Practice
- Health Communication
- High-Throughput Polymorphism
- Rapid Case Identification